iparomlimab + tuvonralimab + regorafenib

This combination therapy consists of QL1706, a bifunctional MabPair product containing the anti-PD-1 monoclonal antibody iparomlimab and the anti-CTLA-4 monoclonal antibody tuvonralimab, administered alongside regorafenib, an oral multi-kinase inhibitor. QL1706 is developed by Qilu Pharmaceutical and is designed to provide dual checkpoint blockade, potentially enhancing the anti-tumor immune response compared to single-agent PD-1 inhibition. Regorafenib, developed by Bayer, targets various kinases involved in tumor angiogenesis (VEGFR1-3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR, FGFR). The triple combination is currently being evaluated in a Phase II clinical trial sponsored by Huai'an First People's Hospital for the treatment of advanced hepatocellular carcinoma (HCC) in patients who have failed prior systemic therapy.

Other names

Iparomlimab and Tuvonralimab Injection (QL1706) in combination with RegorafenibQL1706 plus RegorafenibQL-1706 plus RegorafenibQL 1706 plus Regorafenib